{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:50:33Z","timestamp":1793994633950,"version":"4.8.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate the efficacy and safety of s.c. secukinumab 300\u2009mg combined with standard of care (SoC) in adult patients with active LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The core study was a phase III randomized, placebo-controlled, double-blind study (planned duration: 104\u2009weeks) of patients with active LN. Eligible patients were randomized to receive secukinumab 300\u2009mg or placebo for the first 4\u2009weeks, followed by a monthly maintenance dose, with all patients receiving a SoC background regimen. Patients completing the 104-week treatment of the core study were eligible for an open-label extension study (planned duration: up to 260\u2009weeks) to receive secukinumab 300\u2009mg every 4\u2009weeks. The primary end point of the core study was the proportion of patients achieving complete renal response (CRR) at week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both studies were terminated early, following a planned futility analysis in the core study that showed no clinically meaningful benefit of secukinumab over placebo. In the core study, the proportion of patients achieving CRR at week 52 was lower after receiving secukinumab (24.2%) than after receiving the placebo (36.3%). No differences were observed between the secukinumab and placebo groups in any of the secondary end points of the core study. The incidence of treatment-emergent adverse events was comparable between the secukinumab and placebo groups. In the extension study, the results were not interpretable, owing to the low patient number included in the data analysis (n\u2009=\u200931).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Secukinumab did not demonstrate superior efficacy over placebo in patients with active LN. Secukinumab was well-tolerated with no new or unexpected safety signals detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>https:\/\/clinicaltrials.gov\/study\/NCT04181762, NCT04181762 (Novartis study code: CAIN457Q12301). https:\/\/www.clinicaltrials.gov\/study\/NCT05232864, NCT05232864 (Novartis study code: CAIN457Q12301E1).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf536","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:09:48Z","timestamp":1760360988000},"source":"Crossref","is-referenced-by-count":12,"title":["Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study"],"prefix":"10.1093","volume":"65","author":[{"given":"Ming-hui","family":"Zhao","sequence":"first","affiliation":[{"name":"Renal Division, Peking University First Hospital, Peking University Institute of Nephrology , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidencio","family":"Cons Molina","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Artritis y Osteoporosis , Mexicali,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Aroca","sequence":"additional","affiliation":[{"name":"Renal Division, Simon Bolivar University , Barranquilla,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G","family":"Tektonidou","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anubhav","family":"Mathur","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Tangadpalli","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Private Limited , Hyderabad,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , Bannockburn, IL,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1021-3361","authenticated-orcid":false,"given":"Pascale","family":"Pellet","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Ngoc Phuong Huynh","sequence":"additional","affiliation":[{"name":"Nephrology and Hemodialysis Department, University Medical Center Ho Chi Minh City, University of Medicine and Pharmacy at Ho Chi Minh City , Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2026020205391080100_keaf536-B1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026020205391080100_keaf536-B2","doi-asserted-by":"crossref","first-page":"103418","DOI":"10.1016\/j.autrev.2023.103418","article-title":"When should targeted therapies be used in the treatment of lupus nephritis: early in the disease course or in refractory patients?","volume":"23","author":"Parodis","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2026020205391080100_keaf536-B3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026020205391080100_keaf536-B4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/art.42375","article-title":"Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the Lupus Midwest Network","volume":"75","author":"Hocao\u01e7lu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026020205391080100_keaf536-B5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0961203320932219","article-title":"Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression","volume":"29","author":"Mahajan","year":"2020","journal-title":"Lupus"},{"key":"2026020205391080100_keaf536-B6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: consensus, evidence and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026020205391080100_keaf536-B7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12865-015-0070-7","article-title":"IL-17 and IL-23 in lupus nephritis\u2014association to histopathology and response to treatment","volume":"16","author":"Zickert","year":"2015","journal-title":"BMC Immunol."},{"key":"2026020205391080100_keaf536-B8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00296-010-1771-0","article-title":"Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis","volume":"32","author":"Xing","year":"2012","journal-title":"Rheumatol Int"},{"key":"2026020205391080100_keaf536-B9","doi-asserted-by":"crossref","first-page":"654912","DOI":"10.3389\/fmed.2021.654912","article-title":"The Th17\/IL-17 axis and kidney diseases, with focus on lupus nephritis","volume":"8","author":"Paquissi","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"2026020205391080100_keaf536-B10","first-page":"e20087","article-title":"Current evidence for IL-17\/23 blockade for the treatment of lupus nephritis","volume":"13","author":"Santacruz","year":"2021","journal-title":"Cureus."},{"key":"2026020205391080100_keaf536-B11","author":"Novartis Pharmaceuticals Corporation","year":"2024"},{"key":"2026020205391080100_keaf536-B12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-024-01122-2","article-title":"Safety of secukinumab from 1 million patient-years of exposure: experience from post-marketing setting and clinical trials","volume":"14","author":"Sun","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026020205391080100_keaf536-B13","first-page":"e17198","article-title":"Secukinumab on refractory lupus nephritis","volume":"13","author":"Costa","year":"2021","journal-title":"Cureus"},{"key":"2026020205391080100_keaf536-B14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/0961203318762598","article-title":"A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab","volume":"27","author":"Satoh","year":"2018","journal-title":"Lupus"},{"key":"2026020205391080100_keaf536-B15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3899\/jrheum.161554","article-title":"Renal remission status and long term renal survival in patients with lupus nephritis: a retrospective cohort analysis","volume":"45","author":"Davidson","year":"2018","journal-title":"J Rheumatol"},{"key":"2026020205391080100_keaf536-B16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrneph.2012.220","article-title":"Diagnosis and treatment of lupus nephritis flares\u2014an update","volume":"8","author":"Sprangers","year":"2012","journal-title":"Nat Revi Nephrol"},{"key":"2026020205391080100_keaf536-B17","doi-asserted-by":"crossref","first-page":"e001152","DOI":"10.1136\/lupus-2024-001152","article-title":"Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis","volume":"11","author":"Wong","year":"2024","journal-title":"Lupus Sci Med."},{"key":"2026020205391080100_keaf536-B18","doi-asserted-by":"crossref","first-page":"100688","DOI":"10.1016\/j.xkme.2023.100688","article-title":"Novel therapeutics for management of lupus nephritis: what is next?","volume":"5","author":"Thakare","year":"2023","journal-title":"Kidney Med"},{"key":"2026020205391080100_keaf536-B19","doi-asserted-by":"crossref","first-page":"S771","DOI":"10.1016\/j.ekir.2024.11.1360","article-title":"WCN25-3676 results from the regency trial assessing efficacy and safety of obinutuzumab in active lupus nephritis","volume":"10","author":"Rovin","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026020205391080100_keaf536-B20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/14712598.2018.1504918","article-title":"Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus","volume":"18","author":"Hruskova","year":"2018","journal-title":"Expert Opin Biol Ther."},{"key":"2026020205391080100_keaf536-B21","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf536\/64711702\/keaf536.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf536\/64711702\/keaf536.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf536\/64711702\/keaf536.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:39:19Z","timestamp":1770028759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf536\/8286944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf536","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,15]]},"article-number":"keaf536"}}